Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Turcot syndrome × XELOX × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Rectal Neoplasms 18 Colorectal Neoplasms 16 Stomach Neoplasms 10 Colonic Neoplasms 7 Gastrointestinal Neoplasms 2 Adenocarcinoma 2 Turcot syndrome 1 Recurrence 1 Rcctal Cancer 1 Neoplasms 1 Neoplasm Metastasis 1 Locally Advanced Rectal Cancer (LARC) 1 Locally Advanced Rectal Cancer 1 Locally Advanced Gastric Cancer 1 Locally Advanced Colorectal Cancer 1 Intestinal Neoplasms 1 HER2-positive Locally Advanced Resectable Gastric Cancer 1 HER2-positive Colorectal Cancer 1 Gastrointestinal Diseases 1 Gastric Adenocarcinoma 1 Digestive System Diseases 1 Carcinoma 1 Adebrelimab (SHR-1316) 1

Interventions

Nivolumab 5 pembrolizumab 3 avelumab 3 Neoadjuvant Therapy 3 durvalumab 2 atezolizumab 2 toripalimab 1 spartalizumab 1 relatlimab 1 fludarabine phosphate 1 fludarabine 1 dostarlimab 1 danvatirsen 1 XELOX 1 Surgical Procedures, Operative 1 Oxaliplatin 1 Leucovorin 1 Ipilimumab 1 Induction Chemotherapy 1 Immunotherapy 1 Immunoglobulin G 1 Immune Checkpoint Inhibitors 1 IMM-101 1 Fluorouracil 1 Docetaxel 1 Disulfides 1 DEAE-Dextran 1 Cyclophosphamide 1 Chemotherapy, Adjuvant 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07266025 2026-01-27

CATALIS

Shanghai Zhongshan Hospital

Phase 2 Not yet recruiting

Turcot syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚡